Literature DB >> 21697527

Leveraging crowdsourcing to facilitate the discovery of new medicines.

Thea C Norman, Chas Bountra, Aled M Edwards, Keith R Yamamoto, Stephen H Friend.   

Abstract

Gloomy predictions about the future of pharma have forced the industry to investigate alternative models of drug discovery. Public-private partnerships (PPPs) have the potential to revitalize the discovery and development of first-in-class therapeutics. The new PPP Arch2POCM hopes to foster biomedical innovation through precompetitive validation of pioneer therapeutic targets for human diseases. In this meeting report, we capture insights garnered from the April 2011 Arch2POCM conference.

Entities:  

Mesh：

Year:  2011        PMID： 21697527     DOI： 10.1126/scitranslmed.3002678

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  16 in total

1.  Time to abandon placebo control in pivotal phase III trials?

Authors:  John R Geddes; Andrea Cipriani
Journal:  World Psychiatry       Date:  2015-10       Impact factor: 49.548

2.  Realizing Our Potential in Biobanking: Disease Advocacy Organizations Enliven Translational Research.

Authors:  Kelly A Edwards; Sharon F Terry; Dana Gold; Elizabeth J Horn; Mary Schwartz; Molly Stuart; Suzanne D Vernon
Journal:  Biopreserv Biobank       Date:  2016-04-08       Impact factor: 2.300

3.  The wisdom of crowds.

Authors:  M Castillo
Journal:  AJNR Am J Neuroradiol       Date:  2013-01-04       Impact factor: 3.825

4.  The toolbox is open, but who should pay for the job?

Authors:  John E Ladbury; Adrian Hall; John Skidmore
Journal:  Nat Rev Drug Discov       Date:  2014-07       Impact factor: 84.694

5.  Patent-free pact pushes the boundaries of precompetitive research.

Authors:  Elie Dolgin
Journal:  Nat Med       Date:  2014-06       Impact factor: 53.440

6.  The potential of crowdsourcing to improve patient-centered care.

Authors:  Michael Weiner
Journal:  Patient       Date:  2014       Impact factor: 3.883

7.  Preparedness of the CTSA's structural and scientific assets to support the mission of the National Center for Advancing Translational Sciences (NCATS).

Authors:  Harry Shamoon; David Center; Pamela Davis; Mendel Tuchman; Henry Ginsberg; Robert Califf; David Stephens; Thomas Mellman; Joseph Verbalis; Lee Nadler; Anantha Shekhar; Daniel Ford; Robert Rizza; Reza Shaker; Kathleen Brady; Barbara Murphy; Bruce Cronstein; Judith Hochman; Philip Greenland; Eric Orwoll; Lawrence Sinoway; Harry Greenberg; Rebecca Jackson; Barry Coller; Eric Topol; Lisa Guay-Woodford; Marschall Runge; Robert Clark; Don McClain; Harry Selker; Curtis Lowery; Steven Dubinett; Lars Berglund; Dan Cooper; Gary Firestein; S Clay Johnston; Julian Solway; James Heubi; Ronald Sokol; David Nelson; Larry Tobacman; Gary Rosenthal; Lauren Aaronson; Richard Barohn; Philip Kern; John Sullivan; Thomas Shanley; Bruce Blazar; Richard Larson; Garret FitzGerald; Steven Reis; Thomas Pearson; Thomas Buchanan; David McPherson; Allan Brasier; Robert Toto; Mary Disis; Marc Drezner; Gordon Bernard; John Clore; Bradley Evanoff; Julianne Imperato-McGinley; Robert Sherwin; Jill Pulley
Journal:  Clin Transl Sci       Date:  2012-03-27       Impact factor: 4.689

8.  Learning from hackers: open-source clinical trials.

Authors:  Adam G Dunn; Richard O Day; Kenneth D Mandl; Enrico Coiera
Journal:  Sci Transl Med       Date:  2012-05-02       Impact factor: 17.956

9.  Developing cellular therapies for retinal degenerative diseases.

Authors:  Kapil Bharti; Mahendra Rao; Sara Chandros Hull; David Stroncek; Brian P Brooks; Ellen Feigal; Jan C van Meurs; Christene A Huang; Sheldon S Miller
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-26       Impact factor: 4.799

Review 10.  Cancer Systems Biology: a peek into the future of patient care?

Authors:  Henrica M J Werner; Gordon B Mills; Prahlad T Ram
Journal:  Nat Rev Clin Oncol       Date:  2014-02-04       Impact factor: 66.675
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.